Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Long-Term Investments (2021 - 2023)

TriSalus Life Sciences has reported Long-Term Investments over the past 3 years, most recently at $12.1 million for Q2 2023.

  • For Q2 2023, Long-Term Investments fell 95.18% year-over-year to $12.1 million; the TTM value through Jun 2023 reached $12.1 million, down 95.18%, while the annual FY2022 figure was $19.8 million, 92.07% down from the prior year.
  • Long-Term Investments for Q2 2023 was $12.1 million at TriSalus Life Sciences, down from $20.2 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $251.0 million in Q3 2022 and troughed at $12.1 million in Q2 2023.
  • A 3-year average of $150.5 million and a median of $250.0 million in 2021 define the central range for Long-Term Investments.
  • On a YoY basis, Long-Term Investments climbed as much as 91.91% in 2023 and fell as far as 95.18% in 2023.
  • Year by year, Long-Term Investments stood at $250.0 million in 2021, then crashed by 92.07% to $19.8 million in 2022, then plummeted by 39.09% to $12.1 million in 2023.
  • Business Quant data shows Long-Term Investments for TLSI at $12.1 million in Q2 2023, $20.2 million in Q1 2023, and $19.8 million in Q4 2022.